Grazoprevir
- Generic Name
- Grazoprevir
- Brand Names
- Zepatier
- Drug Type
- Small Molecule
- Chemical Formula
- C38H50N6O9S
- CAS Number
- 1350514-68-9
- Unique Ingredient Identifier
- 8YE81R1X1J
- Background
Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% o...
- Indication
Grazoprevir is indicated in combination with Elbasvir (as the fixed dose combination product Zepatier) with or without Ribavirin for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Chronic hepatitis C genotype 1a, Genotype 4 Chronic Hepatitis C
- Associated Therapies
- -
A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01716156
A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 87
- Registration Number
- NCT01710501
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2438
- Registration Number
- NCT01667081
A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT01537900
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5
- Registration Number
- NCT01440595
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT01390428
Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 368
- Registration Number
- NCT01353911
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00998985
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath